Photo Gallery



News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • SEPTEMBER 2021 Issue has been successfully launched on 1 September 2021.



Cláudia Maria Blanco Moreira Norberg*, Paulo Roberto Blanco Moreira Norberg, Antonio Neres Norberg, Alcemar Antonio Lopes de Matos, Fabiano Guerra Sanches, Fernanda Castro Manhães, Bianca Magnelli Mangiavacchi and Lígia Cordeiro Matos Faial


Despite the high risk of developing fungal co-infections in patients infected with SARS-CoV-2, few studies have been conducted on the incidence and risk of these secondary infections. This research aims to analyse the panorama of co-infections and superinfections caused by species of the genus Candida in patients with COVID-19 and possible involved variables by analysing the current scientific literature. There are signs that the use of anti-inflammatory drugs, corticosteroids and immunomodulators used in the treatment of COVID-19 improved systemic colonization by Candida spp., indicating the need to evaluate the risks and benefits of this therapy according to the patient's clinical situation and levels of nosocomial contamination. Candida auris, a species equipped with virulence, antifungal resistance and environmental colonization attributes, represents a latent risk in co-infections. All research that has evaluated the incidence of Candida spp. infections compared to contemporary or historical control groups indicated a higher incidence of concomitant infections between SARS-CoV-2 and Candida spp. All research that recorded mortality rates for patients presenting with co-infection for these two pathogens also indicates higher levels of fatality when compared to control groups of those infected with either the virus alone or those infected just by these fungi. A review of the literature currently available indicates a considerable increase in cases of systemic Candida colonisation among patients with severe clinical forms of COVID-19 in several locations of the world, which may indicate that there are, with due proportion, twin epidemics of SARS-CoV-2 and Candida spp.

Keywords: COVID-19, SARS-CoV-2, Candida, candidemia, secondary infections.

[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More